Semaglutide Improves Taste Recognition in Women With Obesity and PCOS
In a 16-week randomized study of women with obesity and PCOS, semaglutide improved taste recognition by an estimated 2.5 points versus placebo.
Hormone Insight
Evidence summaries in diabetes, endocrinology, and metabolism for clinicians who need the key data fast.
Latest Evidence
View all PICO summaries
In-Hospital CGM Improves Time in Range in Type 2 Diabetes: DIATEC Trial
In a two-center randomized trial, diabetes-team CGM-guided insulin titration increased inpatient time in range from 62.7% to 77.6% versus point-of-care glucose testing.
AI-Led Diabetes Prevention Program Is Noninferior to Human Coaching
In a phase 3 noninferiority trial, an AI-led Diabetes Prevention Program was noninferior to human coaching for a 12-month composite of weight, physical activity and HbA1c outcomes.
Tirzepatide Added to Basal Insulin Improves Glycemic Control in Type 2 Diabetes
In a 40-week phase 3 trial in China, tirzepatide 10 mg or 15 mg added to basal insulin reduced HbA1c more than placebo, with mainly mild or moderate gastrointestinal events.
Hypoglycemia Prolongs QTc in Type 2 Diabetes and Healthy Adults
A randomized crossover clamp study found that hypoglycemia prolonged QTc, with recovery by 90 minutes after euglycemia and no effect from mineralocorticoid receptor blockade.
Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes: A Randomized Controlled Parallel Intervention Trial.
In a Diabetes Care randomized trial, Sleep-Opt did not improve glycemic targets or sleep parameters, although sleep improved in both intervention groups. Key reported results included A1C and CGM parameters at 12 weeks indicated no significant differences between groups.
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes.
In a Diabetes Care randomized trial, A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications. Key reported results included During 2020 to 2021, 884 participants (mean [SD]...
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
In a JAMA randomized trial, The authors' conclusion is reported in the source abstract. Key reported results included This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female).